Full Press Release Details
SAN DIEGO , June 5, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today published its annual Corporate Social Responsibility (CSR) Report , highlighting the company's commitment to human health, and the progress made by its environmental, social, and governance (ESG) program in 2022.
"Genomics has the ability to improve global health care, sustainability, and equity through better diagnosis and treatment; better representation in genomic data; greater access to personalized medicine; and a deeper understanding of the world," said Francis deSouza, CEO of Illumina. "Guided by our mission, we are taking bold, meaningful steps through our business strategy to accelerate access to genomics, empower our communities, integrate environmental sustainability, nurture our people, and operate responsibly."
Illumina's ESG program is rooted in five key areas, and the company's 2022 CSR report demonstrates progress in each:
The full report is available on the Illumina CSR website . Illumina will host its third annual virtual ESG Investor Event on June 12 ; register here to attend .
Forward-Looking Statements This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding mandates, the future, business plans and other statements that are not historical in nature. These statements are made on the basis of Illumina's views and assumptions regarding future events and business performance and plans as of the time the statements are made. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "project," "target," "will" and other words and terms of similar meaning. Illumina does not undertake any obligation to update these statements unless required by applicable laws or regulations, and you should not place undue reliance on forward-looking statements. Specific factors are set forth in Illumina's Annual Report on Form 10-K for the year ended January 1, 2023 under the caption "Risk Factors", in information disclosed in public conference calls, the date and time of which are released beforehand, and in filings with the Securities and Exchange Commission including, among others, quarterly reports on Form 10-Q.
About Illumina Illumina is improving human health by unlocking the power of the genome. In 2023 we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on Twitter , Facebook , LinkedIn , Instagram , TikTok , and YouTube .
Investors: Salli Schwartz 858-291-6421 [email protected]
Media: David McAlpine 347-327-1336 [email protected]
SOURCE Illumina, Inc.